Breaking News Instant updates and real-time market news.

2022-07-06 10:06:40 $ECON Economic Data / + 10:06 07/06/22 07/06 10:06 07/06/22 10:06	May JOLTS report job openings 11.254M, consensus 11.250M

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Cellebrite price target lowered to $10 from $13 at Cowen » 07:38 08/12/22 08/12 07:38 08/12/22 07:38 CLBT Cellebrite $5.28 / -0.4 (-7.04%) Cowen analyst Shaul Eyal… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CLBT Cellebrite $5.28 / -0.4 (-7.04%) 07/05/22 Cellebrite and Chainalysis launch partnership 06/30/22 Cellebrite announces availability of Cellebrite Physcial Analyzer Ultra Series 05/05/22 Cellebrite announces upcoming release of Cellebrite Premium 04/06/22 Cellebrite announces national police force of EMEA expanded partnership CLBT Cellebrite $5.28 / -0.4 (-7.04%) 07:14 Today William Blair Cellebrite downgraded to Market Perform at William Blair after guidance cut 06:06 Today William Blair Cellebrite downgraded to Market Perform from Outperform at William Blair 05/16/22 Cowen Cellebrite price target lowered to $13 from $17 at Cowen 05/13/22 Deutsche Bank Cellebrite price target lowered to $10 from $11 at Deutsche Bank CLBT Cellebrite $5.28 / -0.4 (-7.04%) 08/11/22 Cellebrite reports Q2 adjusted EPS 0c, consensus 3c 08/11/22 Cellebrite lowers FY22 revenue to $270M-$285M from $285M-$300M 05/12/22 Cellebrite sees FY22 revenue $285M-$300M, consensus $292.06M 05/12/22 Cellebrite reports Q1 adjusted EPS 1c, consensus 2c CLBT Cellebrite $5.28 / -0.4 (-7.04%) 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning 02/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Recommendations	LegalZoom price target lowered to $19 from $24 at Credit Suisse » 07:38 08/12/22 08/12 07:38 08/12/22 07:38 LZ LegalZoom $11.11 / -0.175 (-1.55%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly LZ LegalZoom $11.11 / -0.175 (-1.55%) 03/11/22 LegalZoom trading resumes 03/11/22 LegalZoom trading halted, volatility trading pause 03/10/22 LegalZoom board approves $150M share repurchase program 03/10/22 LegalZoom appoints Block CLO Sivan Whiteley to board of directors LZ LegalZoom $11.11 / -0.175 (-1.55%) 07/28/22 Morgan Stanley LegalZoom downgraded to Underweight on estimate risk at Morgan Stanley 07/28/22 Morgan Stanley LegalZoom downgraded to Underweight from Equal Weight at Morgan Stanley 07/14/22 Morgan Stanley LegalZoom price target lowered to $12 from $13 at Morgan Stanley 04/19/22 Citi LegalZoom assumed with Buy from Neutral at Citi LZ LegalZoom $11.11 / -0.175 (-1.55%) 08/11/22 LegalZoom cuts FY22 revenue view to $612M-$616M from $650-$660M 08/11/22 LegalZoom sees Q3 revenue $149M-$151M, consensus $171.21M 08/11/22 LegalZoom reports Q2 EPS 5c, consensus 2c 05/12/22 LegalZoom sees Q2 revenue $162M-$164M, consensus $165.08M LZ LegalZoom $11.11 / -0.175 (-1.55%) 08/11/22 Fly Intel: After-Hours Movers 03/11/22 What You Missed On Wall Street On Friday 03/11/22 What You Missed On Wall Street This Morning 03/10/22 Fly Intel: After-Hours Movers
Recommendations	Rockley Photonics price target lowered to $14 from $21 at Cowen » 07:37 08/12/22 08/12 07:37 08/12/22 07:37 RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) Cowen analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 08/11/22 Rockley Photonics sees FY22 core product revenue $5M-$10M 08/09/22 Rockley Photonics gets first commercial order for Rockley Bioptx band 07/26/22 Rockley Photonics announces strategic partnership with contract research group 06/16/22 Rockley customer begins evaluation program using its sensing technology RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 06:37 Today Baird Rockley Photonics downgraded to Neutral from Outperform at Baird 06/08/22 Baird to hold a conference 06/07/22 Baird to hold a conference 05/13/22 Needham Rockley Photonics price target lowered to $4 from $8 at Needham RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 08/11/22 Rockley Photonics reports Q2 adjusted EPS (82c), consensus (25c) 06/15/22 Rockley Photonics affirms FY22 revenue guidance 05/12/22 Rockley Photonics reports Q1 adjusted EPS (28c), consensus (25c) 03/08/22 Rockley Photonics sees FY22 revenue $20M-$30M, consensus $24.87M RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 04/22/22 Rockley Photonics falls after Iceberg Research reveals short position 04/22/22 Iceberg Research announces short position in Rockley Photonics RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 04/22/22 What You Missed On Wall Street On Friday 04/22/22 What You Missed On Wall Street This Morning 03/08/22 Fly Intel: After-Hours Movers RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 06/22/22 Largest borrow rate increases among liquid names 05/12/22 Rockley Photonics Holdings options imply 14.2% move in share price post-earnings 03/08/22 Rockley Photonics Holdings options imply 13.6% move in share price post-earnings
Earnings	Axcella Health reports Q2 EPS (40c), consensus (38c) » 07:37 08/12/22 08/12 07:37 08/12/22 07:37 AXLA Axcella Health $2.34 / + (+0.00%) As of June 30, cash, cash… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings AXLA Axcella Health $2.34 / + (+0.00%) 08/02/22 Axcella Health reports results from Phase 2a investigation for AXA1125 05/26/22 Axcella done enrolling of trial for long COVID and prioritize portfolio 02/14/22 Axcella Health receives fast track designation from FDA for AXA1125 AXLA Axcella Health $2.34 / + (+0.00%) 08/03/22 H.C. Wainwright Axcella Health price target lowered to $8 from $14 at H.C. Wainwright 05/09/22 Chardan Axcella Health price target lowered to $7 from $12 at Chardan 10/12/21 Noble Capital Axcella Health initiated with an Outperform at Noble Capital 09/22/21 Goldman Sachs Axcella Health downgraded to Neutral from Buy at Goldman Sachs AXLA Axcella Health $2.34 / + (+0.00%) 05/05/22 Axcella reports Q1 EPS (46c), consensus (39c) 03/30/22 Axcella Health reports Q4 EPS (46c), consensus (45c)
Recommendations	Kore Group price target lowered to $9 from $12.50 at Cowen » 07:35 08/12/22 08/12 07:35 08/12/22 07:35 KORE Kore Group $2.71 / -0.03 (-1.09%) Cowen analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly KORE Kore Group $2.71 / -0.03 (-1.09%) 06/06/22 Kore Group rises 13.9% 03/30/22 Kore Group rises 9.6% 03/22/22 Kore Group promotes Paul Holtz to CFO 02/17/22 Kore Group acquires Business Mobility Partners and SIMON IoT KORE Kore Group $2.71 / -0.03 (-1.09%) 05/17/22 Deutsche Bank Kore Group price target lowered to $6 from $7.50 at Deutsche Bank 04/12/22 Morgan Stanley Kore Group price target lowered to $6.50 from $7.50 at Morgan Stanley 04/12/22 Morgan Stanley Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious 03/10/22 Cowen Kore Group price target lowered to $12.50 from $18 at Cowen KORE Kore Group $2.71 / -0.03 (-1.09%) 08/11/22 Kore Group still sees 2022 revenue $260M-$265M, consensus $267.04M 08/11/22 Kore Group reports Q2 EPS (15c), consensus (7c) 05/16/22 Kore Group reaffirms FY22 revenue view $260M-$265M, consensus $271.55M 05/16/22 Kore Group reports Q1 EPS (15c), consensus (9c) KORE Kore Group $2.71 / -0.03 (-1.09%) 03/29/22 Fly Intel: After-Hours Movers
Earnings	Soligenix reports Q2 EPS (6c), consensus (8c) » 07:34 08/12/22 08/12 07:34 08/12/22 07:34 SNGX Soligenix / + Reports Q2 revenue $0.4M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events SNGX Soligenix / + 07/27/22 Soligenix receives FDA agreement on pediatric study plan for HyBryte in lymphoma 07/25/22 Soligenix signs license agreement with SERB Pharmaceuticals 07/20/22 Soligenix announces results of Phase 3 FLASH study of HyBryte 07/14/22 SERB Pharmaceuticals licenses antigen from Soligenix SNGX Soligenix / + 08/25/21 Alliance Global Partners Soligenix price target lowered to $3.75 from $5.75 at Alliance Global Partners 09/22/22 Soligenix, Inc.
Hot Stocks	Marathon Gold reports Q2 capex C$9.2M vs. C$4.7M last year » 07:33 08/12/22 08/12 07:33 08/12/22 07:33 MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) Matt Manson, President,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) 07/28/22 Marathon Gold publishes first annual sustainability report 07/18/22 Marathon Gold reports key stakeholder agreements for Valentine Gold Project 07/06/22 Marathon Gold announces updated MRE for Valentine Gold Project 06/15/22 Marathon Gold reports first 2022 drill results from Berry, Victory Deposits MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) 07/21/22 National Bank Marathon Gold price target lowered to C$2.50 from C$3.75 at National Bank 07/07/22 Canaccord Marathon Gold price target lowered to C$3.50 from C$3.60 at Canaccord 06/14/22 RBC Capital Marathon Gold price target lowered to C$3.50 from C$4 at RBC Capital 05/16/22 TD Securities Marathon Gold price target lowered to C$3.50 from C$4 at TD Securities MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) 03/25/22 Marathon Gold reports Q4 net loss C$2.37M vs. C$2.88M last year
Recommendations	Taysha Gene Therapies price target lowered to $5 from $9 at Wedbush » 07:33 08/12/22 08/12 07:33 08/12/22 07:33 TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) Wedbush analyst Laura… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 08/11/22 Taysha Gene Therapies expects cash to fund expenses into 4Q23 05/16/22 Taysha Gene Therapies announces upcoming milestones 05/03/22 Taysha Gene Therapies receives orphan drug designation for TSHA-120 04/25/22 Taysha Gene Therapies announces oral presentations at IRSFT, ASCENT meetings TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 05/17/22 Chardan Taysha Gene Therapies price target lowered to $34 from $37 at Chardan 04/01/22 Truist Taysha Gene Therapies price target lowered to $35 from $60 at Truist 03/31/22 Chardan Taysha Gene Therapies price target lowered to $37 from $60 at Chardan 03/09/22 Baird Baird expects positive GAN guide for Taysha Gene Therapies, starts at Outperform TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 08/11/22 Taysha Gene Therapies reports Q2 EPS (84c) vs. ($1.09) last year 05/16/22 Taysha Gene Therapies reports Q1 EPS ($1.31), consensus ($1.07) 03/31/22 Taysha Gene Therapies reports Q4 EPS ($1.32), consensus ($1.25) TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 03/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/03/22 6th Annual Genetic Medicines Conference
Recommendations	Fastly price target lowered to $25 from $35 at Raymond James » 07:32 08/12/22 08/12 07:32 08/12/22 07:32 FSLY Fastly $11.56 / -0.275 (-2.32%) Raymond James analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fastly names Todd Nightingale as CEO effective September 1 07/11/22 Fastly falls -14.0% 07/11/22 Fastly falls -11.4% 05/19/22 Fastly acquires Glitch, terms undisclosed FSLY Fastly $11.56 / -0.275 (-2.32%) 08/04/22 Craig-Hallum Fastly price target lowered to $13 from $19 at Craig-Hallum 07/22/22 Citi Fastly price target lowered to $10 from $14 at Citi 07/19/22 RBC Capital Fastly downgraded to Underperform from Sector Perform at RBC Capital 07/19/22 RBC Capital Fastly downgraded to Underperform from Sector Perform at RBC Capital FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fastly sees FY22 EPS (68c)-(63c), consensus (56c) 08/03/22 Fastly sees Q3 EPS (18c)-(15c), consensus (14c) 08/03/22 Fastly reports Q2 EPS (23c), consensus (17c) 08/03/22 Notable companies reporting after market close FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fly Intel: After-Hours Movers 07/11/22 What You Missed On Wall Street On Monday 07/11/22 What You Missed On Wall Street This Morning 05/05/22 What You Missed On Wall Street On Thursday FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fastly Inc options imply 15.3% move in share price post-earnings 07/01/22 Fastly Inc call volume above normal and directionally bullish 05/16/22 Fastly Inc call volume above normal and directionally bullish 05/04/22 Fastly Inc options imply 16.8% move in share price post-earnings
Recommendations	Leafly price target lowered to $4 from $12 at Cowen » 07:32 08/12/22 08/12 07:32 08/12/22 07:32 LFLY Leafly $2.25 / -0.15 (-6.25%) Cowen analyst Harrison… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options LFLY Leafly $2.25 / -0.15 (-6.25%) 06/24/22 Leafly set to join Russell 3000, Russell 200 Indexes 04/14/22 Leafly names Deidre Boulware Chief People Officer 03/24/22 Leafly Holdings trading resumes 03/24/22 Leafly Holdings trading halted, volatility trading pause LFLY Leafly $2.25 / -0.15 (-6.25%) 06:12 Today Benchmark Leafly price target lowered to $6.50 from $12.00 at Benchmark 05/20/22 Cowen Cowen starts Leafly with Outperform with its early mover advantage 05/20/22 Cowen Leafly initiated with an Outperform at Cowen 05/18/22 Oppenheimer Leafly initiated with a Perform at Oppenheimer LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly sees FY22 revenue $48M-$51M, three estimates $53.55M 08/11/22 Leafly reports Q2 EPS 37c, two estimates (12c) LFLY Leafly $2.25 / -0.15 (-6.25%) 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/07/22 Leafly LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly Holdings options imply 15.4% move in share price post-earnings 08/02/22 Leafly Holdings put volume heavy and directionally bearish 05/23/22 Largest borrow rate increases among liquid names 03/29/22 Leafly Holdings options imply 7.5% move in share price post-earnings

Downgrade	Sally Beauty downgraded to Market Perform at Cowen on risk to FY23 estimates » 07:32 08/12/22 08/12 07:32 08/12/22 07:32 SBH Sally Beauty $15.20 / +0.66 (+4.54%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SBH Sally Beauty $15.20 / +0.66 (+4.54%) 06/16/22 Sally Beauty falls -12.7% SBH Sally Beauty $15.20 / +0.66 (+4.54%) 05:56 Today Cowen Sally Beauty downgraded to Market Perform from Outperform at Cowen 06/29/22 Raymond James Raymond James cuts Sally Beauty to Underperform on exposure low-income consumer 06/29/22 Raymond James Sally Beauty downgraded to Underperform from Market Perform at Raymond James 06/16/22 Morgan Stanley Sally Beauty downgraded to Underweight from Equal Weight at Morgan Stanley SBH Sally Beauty $15.20 / +0.66 (+4.54%) 08/04/22 Sally Beauty lowers FY22 revenue growth view to down 2% from 0%-down 2% 08/04/22 Sally Beauty reports Q3 adjusted EPS 55c, consensus 59c 05/05/22 Sally Beauty lowers FY22 revenue growth view to 0%-down 2% from up 3%-4% 05/05/22 Sally Beauty reports Q2 adjusted EPS 47c, consensus 51c SBH Sally Beauty $15.20 / +0.66 (+4.54%) 06/29/22 What You Missed On Wall Street On Wednesday 06/29/22 What You Missed On Wall Street This Morning 06/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/16/22 What You Missed On Wall Street On Thursday
Downgrade	PagerDuty downgraded to Neutral from Buy at Monness Crespi » 07:31 08/12/22 08/12 07:31 08/12/22 07:31 PD PagerDuty $28.13 / -1.145 (-3.91%) Monness Crespi analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PD PagerDuty $28.13 / -1.145 (-3.91%) 06/29/22 PagerDuty CEO sells $2.11M in common stock 05/24/22 PagerDuty expands international presence to Japan 05/02/22 PagerDuty appoints Katherine Post Calvert as CMO 03/17/22 PagerDuty rises 15.3% PD PagerDuty $28.13 / -1.145 (-3.91%) 07/07/22 Canaccord PagerDuty initiated with a Buy at Canaccord 06/03/22 Craig-Hallum PagerDuty price target lowered to $37 from $45 at Craig-Hallum 06/03/22 Baird PagerDuty price target lowered to $40 from $47 at Baird 05/31/22 RBC Capital PagerDuty price target lowered to $41 from $46 at RBC Capital PD PagerDuty $28.13 / -1.145 (-3.91%) 06/02/22 PagerDuty sees FY23 EPS (21c)-(17c), consensus (20c) 06/02/22 PagerDuty sees Q2 EPS (9c)-(8c), consensus (8c) 06/02/22 PagerDuty reports Q1 EPS (4c), consensus (8c) 03/16/22 PagerDuty sees FY23 adjusted EPS (23c)-(17c), consensus (19c) PD PagerDuty $28.13 / -1.145 (-3.91%) 06/02/22 Fly Intel: After-Hours Movers 03/17/22 What You Missed On Wall Street On Thursday 03/17/22 What You Missed On Wall Street This Morning 03/16/22 Fly Intel: After-Hours Movers 09/01/22 PagerDuty - PD PD PagerDuty $28.13 / -1.145 (-3.91%) 06/02/22 PagerDuty options imply 11.5% move in share price post-earnings 03/16/22 PagerDuty options imply 16.4% move in share price post-earnings
Downgrade	TerrAscend downgraded to Neutral from Overweight at Cantor Fitzgerald » 07:30 08/12/22 08/12 07:30 08/12/22 07:30 TRSSF TerrAscend $2.40 / +0.11 (+4.80%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 06/02/22 TerrAscend debuts Cookies, Gage brands in New Jersey 03/09/22 TerrAscend to close Gage Growth acquisition on March 10 TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 07/22/22 Seaport Global TerrAscend initiated with a Buy at Seaport Global 02/09/22 Clarus TerrAscend price target lowered to C$14 from C$16.25 at Clarus 12/08/21 Cantor Fitzgerald TerrAscend price target raised to $7.65 from $6.70 at Cantor Fitzgerald 11/17/21 Stifel TerrAscend price target lowered to C$21 from C$23 at Stifel TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 04/11/22 NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 04/14/22 Here's What You Missed in Cannabis This Week
Downgrade	NextNav cut to Perform at Oppenheimer on capital needs » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NN NextNav $3.39 / +0.02 (+0.59%) Oppenheimer analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NN NextNav $3.39 / +0.02 (+0.59%) 08/10/22 NextNav appoints Subin as new board member 07/07/22 NextNav enters partnership with VOS Systems 06/13/22 NextNav announces The Vitals App has joined NextNav partner ecosystem 05/19/22 NextNav, Vizsafe partner for vertical location services NN NextNav $3.39 / +0.02 (+0.59%) 06:32 Today Oppenheimer NextNav downgraded to Perform from Outperform at Oppenheimer 05/16/22 R.F. Lafferty NextNav price target lowered to $15 from $16 at R.F. Lafferty 05/13/22 B. Riley NextNav price target lowered to $14.25 from $17 at B. Riley 01/06/22 R.F. Lafferty NextNav initiated with a Buy at R.F. Lafferty NN NextNav $3.39 / +0.02 (+0.59%) 08/10/22 NextNav reports Q2 revenue $1.4M vs. $216,000 last year
Recommendations	Toast price target raised to $27 from $21 at Needham » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 TOST Toast $18.12 / -0.33 (-1.79%) Needham analyst Mayank… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance 07/26/22 Cathie Wood's ARK Investment bought 113K shares of Toast today 07/07/22 Toast acquires employee scheduling, communication solution Sling, no terms 05/13/22 Toast rises 15.2% TOST Toast $18.12 / -0.33 (-1.79%) 07:17 Today KeyBanc Toast price target raised to $25 from $18 at KeyBanc 05/17/22 Mizuho Toast price target lowered to $18 from $19 at Mizuho 05/13/22 Needham Toast price target lowered to $21 from $38 at Needham 05/13/22 Canaccord Toast price target lowered to $25 from $34 at Canaccord TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 08/11/22 Toast sees Q3 revenue $700M-$730M, consensus $665.08M 08/11/22 Toast reports Q2 EPS (11c) vs (64c) last year 08/11/22 Notable companies reporting after market close 22 Sep TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Fly Intel: After-Hours Movers 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast Inc options imply 11.3% move in share price post-earnings 05/12/22 Toast Inc options imply 21.6% move in share price post-earnings 03/04/22 Toast Inc put volume heavy and directionally bearish 02/15/22 Toast Inc options imply 15.0% move in share price post-earnings
Recommendations	Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NKTX Nkarta $15.59 / -0.36 (-2.26%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 04/25/22 Nkarta trading resumes 04/25/22 Nkarta trading halted, volatility trading pause 04/25/22 Nkarta announces preliminary dose finding data for two NK cell programs NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/28/22 Needham Nkarta initiated with a Buy at Needham 07/18/22 SVB Securities Nkarta initiated with an Outperform at SVB Securities 04/26/22 Stifel Nkarta's AML/NHL data 'a positive' for CAR-NK space, says Stifel 04/25/22 Cantor Fitzgerald Nkarta assumed with an Overweight at Cantor Fitzgerald NKTX Nkarta $15.59 / -0.36 (-2.26%) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 05/12/22 Nkarta reports Q1 EPS (79c), consensus (72c) 03/17/22 Nkarta reports Q4 EPS (69c), consensus (90c) 26 Apr NKTX Nkarta $15.59 / -0.36 (-2.26%) 04/26/22 What You Missed On Wall Street On Tuesday 04/26/22 What You Missed On Wall Street This Morning 04/25/22 Fly Intel: After-Hours Movers 04/25/22 What You Missed On Wall Street On Monday NKTX Nkarta $15.59 / -0.36 (-2.26%) 05/04/22 Nkarta call volume above normal and directionally bullish 04/25/22 Unusually active option classes on open April 25th
Initiation	Mereo BioPharma initiated with an Overweight at Cantor Fitzgerald » 07:27 08/12/22 08/12 07:27 08/12/22 07:27 MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 07/05/22 Mereo BioPharma regains compliance with Nasdaq minimum bid price requirement 06/02/22 Mereo announces portfolio prioritization plan, sees cash runway into late 2024 06/02/22 Mereo BioPharma to present data update for Phase 1b/2 ACTIVATE study 05/26/22 Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/06/22 Needham Mereo BioPharma price target lowered to $5 from $10 at Needham MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/17/22 AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports
Recommendations	Shattuck Labs price target lowered to $21 from $31 at Needham » 07:26 08/12/22 08/12 07:26 08/12/22 07:26 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) Needham analyst Chad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024 05/12/22 Shattuck Labs sees cash, equivalents funding operations into 2H24 04/08/22 Shattuck Labs presents preclinical SL-9258 data at AACR 03/15/22 Shattuck Labs expects cash to fund operations into 2H24 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Citi Shattuck Labs initiated with a Buy at Citi 05/02/22 H.C. Wainwright Shattuck Labs initiated with a Buy at H.C. Wainwright STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs reports Q2 EPS (65c), consensus (59c) 05/12/22 Shattuck Labs reports Q1 EPS (58c), consensus (50c) 03/15/22 Shattuck Labs reports Q4 EPS 18c, two est. (43c) STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Lennar downgraded to Neutral from Outperform at Wedbush » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 LEN Lennar $87.78 / +0.47 (+0.54%) Wedbush analyst Jay… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options LEN Lennar $87.78 / +0.47 (+0.54%) 06/26/22 Fly Intel: Top five weekend stock stories 06/21/22 Housing market has cooled as expected, Lennar says 06/21/22 Lennar sees Q3 deliveries 17,000-18,500 03/17/22 Lennar raises FY gross margin view to 27.25%-28% from 27%-27.5% LEN Lennar $87.78 / +0.47 (+0.54%) 06:32 Today Wedbush Lennar downgraded to Neutral from Outperform at Wedbush 07/12/22 JPMorgan JPMorgan 'cautious and less constructive' on homebuilders, downgrades Lennar 07/12/22 JPMorgan Lennar downgraded to Neutral from Overweight at JPMorgan 06/22/22 UBS Lennar price target lowered to $106 from $108 at UBS LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 Lennar sees Q3 EPS $4.55-$5.45, consensus $4.78 06/21/22 Lennar reports Q2 EPS $4.49, consensus $3.98 03/17/22 Lennar sees Q2 EPS $3.80-$4.00, consensus $3.75 03/16/22 Lennar sees FY22 deliveries about 68,000 LEN Lennar $87.78 / +0.47 (+0.54%) 06/25/22 Lennar, Nucor among home-building and steel stocks worth a look, Barron's says 04/14/22 Mortgage rates spike to 5% amid post-pandemic price pressures, NY Times says LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 What You Missed On Wall Street On Tuesday 06/21/22 What You Missed On Wall Street This Morning 06/21/22 Fly Intel: Pre-market Movers 03/17/22 What You Missed On Wall Street On Thursday LEN Lennar $87.78 / +0.47 (+0.54%) 07/01/22 Early notable gainers among liquid option names on July 1st 06/23/22 Early notable gainers among liquid option names on June 23rd 06/22/22 Early notable gainers among liquid option names on June 22nd 05/25/22 Early notable gainers among liquid option names on May 25th
Hot Stocks	GreenLight Bioscences announces $109M financing » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) GreenLight Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) 08/01/22 GreenLight, Samsung Biologics complete run for mRNA production partnership 08/01/22 GreenLight Bioscences' COVID-19 vaccine completes first engineering run 07/29/22 GreenLight Bioscences to collaborate on COVID-19 vaccine development with NIH 03/14/22 GreenLight enters into licensing agreement with Serum Institute of India

Hot Stocks	ARC Group says RM2 continues to experience 'record demand' for BLOCKPal pallets » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 ARCW ARC Group $1.00 / + (+0.00%) ARC Group Worldwide… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Hot Stocks	Aptinyx announces NYX-2925 study did not achieve primary endpoint » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 APTX Aptinyx / + Aptinyx announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTX Aptinyx / + 04/20/22 Aptinyx says NYX-783 data suggest potential as a treatment for PTSD 04/07/22 Aptinyx trading resumes 04/07/22 Aptinyx trading halted, news pending 04/07/22 Aptinyx announces NYX-2925 study did not achieve primary endpoint APTX Aptinyx / + 05/18/22 Piper Sandler Aptinyx price target lowered to $6 from $10 at Piper Sandler 04/14/22 H.C. Wainwright Aptinyx price target lowered to $2 from $8 at H.C. Wainwright 04/08/22 BMO Capital Aptinyx price target lowered to $6 from $12 at BMO Capital 04/08/22 Truist Aptinyx price target lowered to $5 from $12 at Truist APTX Aptinyx / + 08/04/22 Aptinyx reports Q2 EPS (26c), consensus (28c) 05/12/22 Aptinyx reports Q1 EPS (29c), consensus (30c) 03/23/22 Aptinyx reports Q4 EPS (29c), consensus (35c) APTX Aptinyx / + 03/23/22 Aptinyx options imply 6.9% move in share price post-earnings
Hot Stocks	Unity: UBX1325 injection led to clinically meaningful improvement in mean BCVA » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 UBX Unity Biotechnology / + UNITY Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology announces anticipated milestones 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Downgrade	Diebold downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 DBD Diebold $4.46 / -0.13 (-2.83%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Diebold rises 23.3% 05/10/22 Diebold expects to see cost savings of $150M in the next 12-18 months 03/17/22 Diebold: Shipments, sales into Russia suspended since start of Ukraine crisis DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Wedbush Wedbush upgrades Diebold, sees sales and earnings positioned to improve 07/08/22 Wedbush Diebold upgraded to Outperform from Neutral at Wedbush 05/10/22 JPMorgan Diebold downgraded to Neutral at JPMorgan after 'material' guidance cut 05/10/22 JPMorgan Diebold downgraded to Neutral from Overweight at JPMorgan DBD Diebold $4.46 / -0.13 (-2.83%) 08/02/22 Diebold lowers FY22 revenue view to $3.55B-$3.75B from $3.7B-$3.9B 08/02/22 Diebold reports Q2 non-GAAP EPS 38c, consensus (14c) 05/10/22 Diebold lowers FY22 revenue view to $3.7B-$3.9B from $4.0B-$4.2B 05/10/22 Diebold reports Q1 non-GAAP EPS ($1.61), consensus (21c) DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Plexus downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 PLXS Plexus $95.69 / +0.88 (+0.93%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PLXS Plexus $95.69 / +0.88 (+0.93%) 08/08/22 Plexus opens manufacturing facility in Bangkok, Thailand PLXS Plexus $95.69 / +0.88 (+0.93%) 07/29/22 Needham Plexus price target raised to $105 from $93 at Needham 07/27/22 Benchmark Plexus initiated with a Buy at Benchmark 06/07/22 Raymond James Plexus upgraded to Outperform from Market Perform at Raymond James 01/28/22 Needham Plexus price target lowered to $90 from $95 at Needham PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Plexus sees Q4 GAAP EPS $1.19-$1.35, consensus $1.10 07/27/22 Plexus reports Q3 adjusted EPS $1.33, consensus $1.10 04/27/22 Plexus reports Q2 EPS 95c, consensus 99c 03/07/22 Plexus reaffirms Q2 EPS guidance 76c-92c, consensus 99c PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/24/22 Plexus

Events

Earnings calls, analyst events, roadshows and more

CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

May JOLTS report job openings 11.254M, consensus 11.250M

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access